StreetAlpha.app
Home › Stocks › GMAB

Genmab a (GMAB)

Healthcare
$51.96
▲ +0.76%
LAST CLOSE · NOV 17

Genmab develops antibody therapies, including cancer treatments, from its base in Copenhagen, Denmark. It last closed at $51.96 on Nov 17, up 0.76% on the day. The average 12-month price target from 5 analysts is $65.00 (+25.1% from the last close), with a high of $80.00 and a low of $52.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 6 whale options trades in GMAB, 67% of them bullish and 33% bearish. In the past 30 days there were 7 dark pool prints totaling $14.4M, the largest $5.4M.

AI Auto Pilots
Is GMAB in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$3.7B
+19.2% vs a year ago
Net income
$963.0M
−15.0% vs a year ago
Free cash flow
$1.1B
30.9% margin
Operating margin
28.6%
$1.1B operating income
Balance sheet
Cash & equivalents
$1.7B
At Dec 31
Debt
$5.3B
At Dec 31
Shareholder equity
$5.8B
ExchangeNasdaq
Financials history
FY2023: $2.4B$2.4BFY2023FY2024: $3.1B$3.1BFY2024FY2025: $3.7B$3.7BFY2025

From GMAB's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 17). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
4 Buy1 Hold0 Sell
Each firm's latest rating on GMAB in the past 90 days
Average 12-month target
$65.00
▲ 25.1% upside

Based on 5 analysts who set a price target on GMAB in the past 90 days. The average target is $65.00, with a high of $80.00 and a low of $52.00, compared with the last close of $51.96.

$22$43$63$84PAST 16 TRADING DAYS12-MONTH TARGETSHIGH $80AVG $65LOW $52Jun 23LAST CLOSE+12 MO$22$43$63$84PAST 16 DAYSTARGETSHIGH $80AVG $65LOW $52Jun 23LAST CLOSE+12 MO
Highest target$80.00
Average target$65.00
Lowest target$52.00
Latest rating changes
Morgan StanleyTarget lowered
Nov 13Hold$57 → $56
Morgan StanleyTarget raised
Oct 30Hold$34 → $57
GuggenheimTarget raised
Oct 30Buy$58 → $80
Truist SecuritiesReiterated
Oct 29Buy$67
HC Wainwright & Co.Target raised
Oct 29Buy$50 → $70
DateFirmActionRatingPrice target
Nov 13Morgan StanleyTarget loweredHold$57 → $56
Oct 30Morgan StanleyTarget raisedHold$34 → $57
Oct 30GuggenheimTarget raisedBuy$58 → $80
Oct 29Truist SecuritiesReiteratedBuy$67
Oct 29HC Wainwright & Co.Target raisedBuy$50 → $70
Loading…

Technical Analysis

GMAB · as of the Nov 17 close · updated after every close
Uptrend

The stock is 1% above its 20 day and 19% above its 50 day average. It is 39% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 60). The nearest support is the Pivot at $51.64, and the nearest resistance the Pivot R1 at $52.40.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityHigh, 4.2%/day
Key levels
$59.9752 week high+15.4%
$59.97Swing high (Oct 28)+15.4%
$52.40Pivot R1+0.8%
$51.96Last close
$51.64Pivot−0.6%
$51.2920 day average−1.3%
$51.22Swing low (Nov 6)−1.4%
$51.20Pivot S1−1.5%
$41.8850 day average−19.4%
$36.22100 day average−30.3%
$31.73200 day average−38.9%
$23.6252 week low−54.5%
Indicators
RSI (14)60.41Strong, overbought above 70Neutral
MACD3.25Below its signal lineBearish
Stochastic35.8Middle of its rangeNeutral
ADX (14)43.5Strong uptrend
Williams %R-85.2Oversold below −80, overbought above −20Oversold
CCI (20)8.4Oversold below −100, overbought above 100Neutral
Rate of change−6.4%Change over 10 sessionsBearish
ATR (14)$2.18Typical daily range, 4.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for GMAB

What happened before

See how GMAB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish4 bullish and 2 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow GMAB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How GMAB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2009.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
6
Bullish
4
67%
Bearish
2
33%
Date span
Aug 26 – Oct 27
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
7
Notional
$14.4M
Largest print
$5.4M
Loading…

GMAB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲191 buying vs 123 selling
  • ▲Shares held by funds +30.1%
  • ▲Funds holding +38
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 0.01 to 0.15
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding331293+13.0%
In funds' top 1075+40.0%
Held by funds–––
New / increased74 / 11746 / 102+29.1%
Reduced / sold out88 / 35100 / 31−6.1%
Put/call ratio0.150.01+1668.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GMAB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GMAB is in one of them and how their past GMAB trades turned out.

GMAB in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GMAB in an article yet. Here's the latest on the wider market.

GMAB Congress Trades

All congress trades →
Trades, 12 months
1
Buys
1
100%
Sells
0
0%
People
1
Last filed Jul 21
Who traded GMAB · since 2020
Latest 5 filings of 14
$1K – $15KTraded Mar 30, 2026Filed Jul 21, 2026
$1K – $15KTraded Jan 16, 2025Filed Feb 11, 2025
$1K – $15KTraded Jan 15, 2025Filed Feb 9, 2025
$1K – $15KTraded Dec 16, 2024Filed Jan 14, 2025
$1K – $15KTraded Jul 19, 2024Filed Aug 15, 2024
PersonTypeAmountTradedFiledDelay
Alan ArmstrongHouseBuy$1K – $15KMar 30, 2026Jul 21, 2026113 d
Josh GottheimerD · NJBuy$1K – $15KJan 16, 2025Feb 11, 202526 d
Josh GottheimerD · NJBuy$1K – $15KJan 15, 2025Feb 9, 202525 d
Josh GottheimerD · NJSell$1K – $15KDec 16, 2024Jan 14, 202529 d
Josh GottheimerD · NJBuy$1K – $15KJul 19, 2024Aug 15, 202427 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Genmab a

Genmab is a biopharmaceutical company based in Copenhagen, Denmark. It develops antibody therapies, including treatments for cancer, and sells some products of its own while also working with collaboration partners who commercialize certain products. The company also uses data science and artificial intelligence to help find new drug targets and biomarkers.

Headquarters
1253 Copenhagen K, Denmark